OTIC Key Statistics, Chart & Performance
The current stock price of OTIC is 0.077 USD. In the past month the price decreased by -29.87%. In the past year, price decreased by -96.65%.
OTIC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.37 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.69 | 492.44B | ||
| MRK | MERCK & CO. INC. | 12.55 | 274.34B | ||
| PFE | PFIZER INC | 7.96 | 144.87B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.72B | ||
| ZTS | ZOETIS INC | 20.06 | 56.04B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.77 | 23.19B | ||
| VTRS | VIATRIS INC | 5.48 | 14.70B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.45 | 11.66B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.54B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.53B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.05B |
Related stock screener links
About OTIC
Company Profile
Otonomy, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 51 full-time employees. The company went IPO on 2014-08-13. The firm is focused on the development of therapeutics for neurotology. The firm pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery for the treatment of patients with acute otitis externa (AOE). OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Menieres disease. OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in in Phase II for tinnitus. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in Phase IIa development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss. OTO-825, a gene therapy for congenital hearing loss.
Company Info
OTONOMY INC
5626 Oberlin Drive, Suite 100
San Diego CALIFORNIA 92121 US
CEO: David A. Weber
Employees: 51
Phone: 18587687823.0
OTONOMY INC / OTIC FAQ
What does OTIC do?
Otonomy, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 51 full-time employees. The company went IPO on 2014-08-13. The firm is focused on the development of therapeutics for neurotology. The firm pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery for the treatment of patients with acute otitis externa (AOE). OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Menieres disease. OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in in Phase II for tinnitus. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in Phase IIa development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss. OTO-825, a gene therapy for congenital hearing loss.
Can you provide the latest stock price for OTONOMY INC?
The current stock price of OTIC is 0.077 USD. The price decreased by -11.19% in the last trading session.
Does OTIC stock pay dividends?
OTIC does not pay a dividend.
What is the ChartMill technical and fundamental rating of OTIC stock?
OTIC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the market cap for OTONOMY INC?
OTONOMY INC (OTIC) has a market capitalization of 4.40M USD. This makes OTIC a Nano Cap stock.
What is the next earnings date for OTIC stock?
OTONOMY INC (OTIC) will report earnings on 2023-02-27.
OTIC Technical Analysis
OTIC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to OTIC. Both the profitability and financial health of OTIC have multiple concerns.
OTIC Financial Highlights
Over the last trailing twelve months OTIC reported a non-GAAP Earnings per Share(EPS) of -0.77. The EPS increased by 4.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.01 |
OTIC Forecast & Estimates
9 analysts have analysed OTIC and the average price target is 9.18 USD. This implies a price increase of 11822.08% is expected in the next year compared to the current price of 0.077.
For the next year, analysts expect an EPS growth of 3.04% and a revenue growth -100% for OTIC